Clinical trials
Pulmonary Hypertension clinical trials
Below are recruiting pulmonary hypertension clinical trials, each written for real people, not researchers. We’re tracking 238 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06646250Recruiting
New ultrasound for steady brain monitoring in newborns
This trial uses a new ultrasound device (NeoDoppler) to watch blood flow in a baby's brain continuously. It aims to see if this gentle, bedside tool can help doctors monitor babies—especially those born early or with certain health concerns—without moving them.
TrondheimAges birth–1 year - NCT06753981Recruiting
Triple drug therapy for new PAH patients
This trial tests whether a combination of three medications works well and is safe for people newly diagnosed with pulmonary arterial hypertension (PAH) that is not low-risk. It aims to see if starting with triple therapy early can improve outcomes.
Jinan, ShandongAges 18–80 - NCT06832163Recruiting
Smart weaning from inhaled nitric oxide for newborns with PPHN
This trial tests a new, smart way to slowly reduce (wean) the inhaled nitric oxide gas that helps babies with a serious lung condition called PPHN. If your baby is already responding well to iNO and needs it for at least 24 hours, this study might help make the weaning process safer and more effective.
ShanghaiAges Any age - NCT06899815RecruitingPhase 1
Early safety study of F230 tablets in healthy volunteers
This trial tests a new medicine, F230, in healthy people for the first time. The goal is to check how safe it is and how the body handles it. You might consider this if you are a healthy adult looking to help advance medical research.
Hubei, WuhanAges 18–45 - NCT06947473RecruitingPhase 1/Phase 2
CAR T-cell therapy for lupus, sclerosis, and Sjogren's
This trial tests a new type of immune cell therapy (CAR T-cells from umbilical cord blood) for people with certain autoimmune diseases that haven't responded to standard treatments. It aims to see if targeting two proteins (CD19 and BCMA) can help calm the overactive immune system.
Beijing, Beijing MunicipalityAges 6–65 - NCT07057466Recruiting
AI heart check for hidden valve, pressure, or pump problems
This study uses an artificial intelligence (AI) program to read your ECG (a heart tracing) and detect early signs of heart failure, high blood pressure in the lungs, or valve disease before you have symptoms. The goal is to see if AI can catch these problems early.
BristolAges 18–90 - NCT07161908Recruiting
Remote oxygen monitoring for preterm infants with BPD
This study tests a way to monitor and adjust oxygen therapy from home for premature babies with a long-term lung condition called bronchopulmonary dysplasia. The goal is to see if remote monitoring can improve oxygen management and reduce complications.
České Budějovice, Czech RepublicAges Up to 8 months - NCT07224906Recruiting
Observing patients having a right heart catheterization
This study observes people who are already scheduled for a right heart catheterization, a procedure that checks the pressure in your heart. It helps doctors learn more about heart conditions without adding any extra treatments or procedures.
Boulder, ColoradoAges 18 years+ - NCT07311044Recruiting
Heart health and voice study at Mayo Clinic
This study at Mayo Clinic looks at how heart and lung blood pressure (cardiovascular/pulmonary hypertension) might relate to voice characteristics. Researchers will use voice recordings from people having routine echocardiograms to see if voice changes can help detect heart problems earlier.
Rochester, MinnesotaAges 18 years+ - NCT07333183RecruitingPhase 2
Mosliciguat plus treprostinil for lung disease with pulmonary hypertension
This trial tests a new medicine called mosliciguat combined with an inhaled treatment (treprostinil) for people who have both scarring lung disease (interstitial lung disease) and high blood pressure in the lungs. It aims to see if this combination can improve how well you feel and function.
Kissimmee, FloridaAges 18–85 - NCT07477197Recruiting
Heart Institute Biobank for Adult Congenital Heart Disease
This study collects blood and tissue samples and health information from adults with or at risk for congenital heart disease or related heart conditions. It aims to help researchers better understand these conditions and improve future treatments.
Cincinnati, OhioAges 16 years+ - NCT07285655RecruitingPhase 3
Study of L606 for lung disease with high blood pressure in the lungs
This trial tests a new treatment called L606 for people who have both a type of lung disease (ILD) and high blood pressure in the lungs (PH). The goal is to see if it is safe and helps with exercise and breathing.
Scottsdale, ArizonaAges 18–80 - NCT07556185Recruiting
Testing a home heart health monitoring app for kids
This study tests whether young people with heart conditions can use a home monitoring app called Medly to track their symptoms and weight. The app may help doctors catch problems earlier and keep kids healthier at home.
Toronto, OntarioAges 8–18 - NCT07445347Enrolling by invitation
Bevacizumab for severe HHT liver issues with high heart output
This study looks at how well the drug Bevacizumab works and how safe it is for people with HHT who have severe liver problems that cause their heart to pump too much blood. It aims to help doctors understand if this treatment can help manage these serious symptoms.
PoitiersAges 18 years+ - NCT03149341Enrolling by invitation
MRI and computer-heart simulations for heart disease
This study uses MRI scans and computer simulations to learn more about how the heart and blood flow work in people with certain heart or lung conditions. It may help researchers better understand heart problems and improve future care.
Palo Alto, CaliforniaAges Any age - NCT06544148Recruiting
Measuring lung artery pressure with a chest belt in ICU patients
This study tests a new way to measure blood pressure in your lung artery using a special belt that sends small electrical signals through your chest. It may help doctors monitor your heart and lungs without extra invasive procedures.
BernAges 18 years+ - NCT07613099RecruitingPhase 3
Testing a new PET scan to detect lung and heart scarring
This study tests a new imaging scan (called 18F-FAPI PET/CT) that may help detect scarring in the lungs, heart, or blood vessels. If you have a heart, lung, or blood vessel condition that could cause scarring, this scan might show damage earlier and help doctors plan better treatment.
Bethesda, MarylandAges 18–100 - NCT05967299RecruitingPhase 1
IV ZMA001 study in healthy adults
This Phase 1 trial tests how an IV medicine called ZMA001 behaves in healthy people and checks for early safety. It may help future studies of the drug by confirming dosing and effects in people before testing in patients.
Bethesda, MarylandAges 18–60 - NCT07623525RecruitingPhase 1/Phase 2
DIAG723 study for hereditary hemorrhagic telangiectasia
This study tests a new drug called DIAG723 in adults with hereditary hemorrhagic telangiectasia (HHT), a genetic condition that causes abnormal blood vessels and bleeding. Depending on which part of the study you qualify for, the drug may help reduce nosebleeds, improve anemia, or help with lung blood vessel problems caused by HHT.
Camperdown, New South WalesAges 18 years+ - NCT06274801RecruitingPhase 3
Long-term study of seralutinib for pulmonary arterial hypertension
This trial is for people with pulmonary arterial hypertension (PAH) who have already completed a previous study of the drug seralutinib. It offers continued access to the treatment so doctors can watch its safety and effects over a longer time.
Fresno, CaliforniaAges 18–75 - NCT06649110RecruitingPhase 1/Phase 2
A study of LTP001 for healthy people and those with PAH
This study tests an investigational medicine called LTP001 for pulmonary arterial hypertension (PAH). Part A checks safety in healthy volunteers, and Part B tests if it helps people with PAH by improving blood flow in the lungs.
Scottsdale, ArizonaAges 18–100 - NCT04062565RecruitingPhase 3
Testing treprostinil plus riociguat for advanced pulmonary artery hypertension
This study tests whether taking injected treprostinil together with riociguat can improve how the heart and lung blood vessels work in people with advanced pulmonary artery hypertension (PAH). It may help improve blood-flow measurements and the structure of the heart.
Tucson, ArizonaAges 18 years+ - NCT05452889RecruitingEarly Phase 1
PET scan study in pulmonary hypertension related to scleroderma
This early study uses a PET scan (a type of imaging test) to better understand lung blood-vessel disease in people who have pulmonary hypertension related to scleroderma. It may help researchers find how imaging signals relate to disease and risk.
Pittsburgh, PennsylvaniaAges 18–75 - NCT06317805RecruitingPhase 4
Three-medicine start vs. two oral pills for new PAH
This study compares starting treatment with three medicines, including a continuous infusion (treprostinil), versus two oral medicines for people newly diagnosed with moderate-to-high risk pulmonary arterial hypertension (PAH). The goal is to see which approach improves heart function and symptoms more effectively.
LinzAges 18–70
Hear when a new Pulmonary Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pulmonary hypertension?
- Yes. Clin2 currently lists 238 recruiting pulmonary hypertension studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pulmonary hypertension trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pulmonary hypertension trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Pulmonary Arterial Hypertension
- Chronic Thromboembolic Pulmonary Hypertension
- Pulmonary Artery Hypertension
- Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
- Idiopathic Pulmonary Arterial Hypertension
- Pulmonary Hypertension Due to Lung Diseases and Hypoxia
- Pulmonary Hypertension (Diagnosis)
- Pulmonary Hypertension Due to Left Heart Disease
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.